Major Changes to the 2017 Revision of the World Health Organization Classification of Myeloproliferative Neoplasms.
10.3904/kjm.2018.93.4.351
- Author:
Mi Ae JANG
1
Author Information
1. Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea. miaeyaho@schmc.ac.kr
- Publication Type:Review
- Keywords:
Essential thrombocythemia;
Myeloproliferative disorders;
Polycythemia vera;
Primary myelofibrosis;
World Health Organization
- MeSH:
Classification;
Diagnosis;
Global Health*;
Lymphoid Tissue;
Myeloproliferative Disorders;
Polycythemia Vera;
Primary Myelofibrosis;
Thrombocythemia, Essential;
World Health Organization*
- From:Korean Journal of Medicine
2018;93(4):351-359
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The World Health Organization (WHO) Classification of Tumors of Haematopoietic and Lymphoid Tissues was recently published in a revised fourth edition. The categories of myeloproliferative neoplasms (MPNs) have not significantly changed since the 2008 fourth edition of the classification; however, newly discovered mutations including CALR and CSF3R and improved characterizations and standardizations of morphological features of some entities, particularly BCR-ABL1-negative MPNs, have impacted the diagnostic criteria of disease entities, increasing the reliability and reproducibility of diagnoses. The 2017 revised edition attempts to incorporate new clinical, prognostic, morphologic, and genetic data that have emerged since the last edition. This article reviews the major changes in the classification and their rationale for MPN classification within the revised 2017 WHO system.
